arrow_back Back to App

Easier Access to Medicines: Faster Generics and Imports

This act aims to improve access to prescription drugs, especially during shortages or in markets with limited competition. It allows for quicker approval of generic alternatives and temporary importation of drugs from abroad, potentially lowering costs and increasing availability for citizens. This directly impacts personal health and finances by ensuring essential medications are more accessible and affordable.
Key points
Faster Generic Drug Approval: The act speeds up the process for bringing cheaper generic versions of drugs to market, potentially lowering prices and increasing availability.
Temporary Drug Importation: In cases of drug shortages in the U.S., the act allows for temporary importation of drugs from other countries to prevent supply gaps.
Support for Low-Competition Markets: The act identifies drug markets with limited competition and introduces mechanisms to facilitate drug access in such situations, potentially leading to more options for patients.
Increased Transparency: It requires reporting on the number of drugs authorized for temporary importation, enhancing oversight of the pharmaceutical market.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_2345
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2025-07-17
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Short on Competition Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_2345.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-07-17.

What are the main provisions?

Key points include:

  • Faster Generic Drug Approval: The act speeds up the process for bringing cheaper generic versions of drugs to market, potentially lowering prices and increasing availability.
  • Temporary Drug Importation: In cases of drug shortages in the U.S., the act allows for temporary importation of drugs from other countries to prevent supply gaps.
  • Support for Low-Competition Markets: The act identifies drug markets with limited competition and introduces mechanisms to facilitate drug access in such situations, potentially leading to more options for patients.
  • Increased Transparency: It requires reporting on the number of drugs authorized for temporary importation, enhancing oversight of the pharmaceutical market.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health